Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Inclusion Criteria42

• Age ≥ 70 years old.
• New or progressive cancer (breast, lung, colorectal, prostate), histologically proven or strong clinical suspicion, fulfilling the tumor specific criteria.
• Estimated life expectancy greater than 6 months.
• Patients must be willing and able to comply with study procedures.
• Voluntarily signed and dated written informed consents prior to any study specific procedure.
• QLQ-C30 Quality of Life Questionnaire fully completed at baseline, before inclusion.
• Patients affiliated with a French social security scheme in accordance with the French law on biomedical research (Article 1121-11 of the French Code of Public health).
• Non-metastatic breast cancer (M0):
• \- No prior treatment for the current breast cancer.
• \- All 3 criteria required:
• o Clinical staging: cT2-3-4 Nany, or cTany N1-2-3;
• The cancer specialist considers\* surgery;
• The cancer specialist considers\* radiotherapy and/or chemotherapy. 9.2. Metastatic breast cancer (M1): Both criteria required:
• The cancer specialist considers\* chemotherapy or PARP-inhibitors or mTOR-inhibitors / PIK3CA inhibitors; Previous endocrine therapy +/- CDK4/6 inhibitors is allowed;
• The patient received maximum 1 prior line of chemotherapy for metastatic disease.
• 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
• Non-metastatic colorectal cancer (M0):
• \- No prior therapy for the current tumor in the recruiting hospital
• At least one of the 3 criteria required:
• o The cancer specialist considers\* surgery;
• The cancer specialist considers\* radiotherapy;
• The cancer specialist considers\* chemotherapy and/or immunotherapy. 10.2. Metastatic colorectal cancer (M1):
• The cancer specialist considers\* first or second line systemic therapy and/or radiotherapy (+/- surgery). No previous chemotherapy allowed except adjuvant/perioperative chemotherapy stopped for more than 12 months.
• 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
• Non-metastatic lung cancer (M0):
• No prior therapy for the current tumor in the recruiting hospital
• At least one of the 3 criteria required:
• The cancer specialist considers\* surgery (patients considered for treatment with percutaneous thermoablation alone are not eligible);
• The cancer specialist considers\* radiotherapy (except SBRT);
• The cancer specialist considers\* systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered\* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.
• Metastatic lung cancer (M1):
• The cancer specialist considers\* first or second line systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered\* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.
• \*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
• First diagnosis M0 prostate cancer (no therapy received yet for prostate cancer): at least one of the 2 criteria required:
• o The cancer specialist considers\* radiotherapy;
• o The cancer specialist considers\* hormone therapy (ADT +/- combination Abiraterone and Prednisone).
• Salvage treatment M0 prostate cancer (received prior surgery at least 6 months before):
• o The cancer specialist considers\* radiotherapy (+/- ADT)
• Non-metastatic castration resistant prostate cancer:
• The cancer specialist considers\* treatment intensification (ADT + Enzalutamide or Apalutamide or Darolutamide).
• Metastatic prostate cancer (M1): - The cancer specialist considers\* treatment with Abiraterone or Enzalutamide or Apalutamide, or Docetaxel or Cabazitaxel or PARP-inhibitors or Lutetium PSMA.
• \*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.